Clinical Trials Directory

Trials / Completed

CompletedNCT00703261

Evaluate the Utility of 18FDG-PET as a Tool to Quantify Atherosclerotic Plaque (MK-0000-081 AM3)(COMPLETED)

A Randomized, Double-Blind, Parallel Group Study to Evaluate the Effects of High Dose Statin Therapy on 18Fluorine Fluorodeoxyglucose (18FDG) Uptake in Arteries of Patients With Atherosclerotic Vascular Disease

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
83 (actual)
Sponsor
Merck Sharp & Dohme LLC · Industry
Sex
All
Age
30 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the utility of 18Fluorine Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET) as a tool to quantify atherosclerotic plaque.

Conditions

Interventions

TypeNameDescription
DRUGatorvastatinParticipants will be asked to self-administer one atorvastatin 10 mg or 80 mg tablet at approximately the same time each day.
DRUGplaceboParticipants will be asked to self-administer one tablet of placebo to atorvastatin 10 mg or 80 mg at approximately the same time each day.

Timeline

Start date
2008-08-01
Primary completion
2009-12-01
Completion
2009-12-01
First posted
2008-06-23
Last updated
2015-10-09
Results posted
2011-11-30

Source: ClinicalTrials.gov record NCT00703261. Inclusion in this directory is not an endorsement.

Evaluate the Utility of 18FDG-PET as a Tool to Quantify Atherosclerotic Plaque (MK-0000-081 AM3)(COMPLETED) (NCT00703261) · Clinical Trials Directory